Thursday 1 October 2015

Unrelated Blogger Comments


2 comments:

  1. Any news on the cladribine front? How does it compare to rituximab in terms of relative efficacy?

    ReplyDelete
    Replies
    1. Merck is going back to the EMA to get movectro approaved. In terms of efficacy an rituxumab I believe they will be comparable for RRMS but cladribine can get into the CNS and this will not be the case for rituximab

      Delete